Identify genetic predictive factors for neoadjuvant chemotherapy in patients with luminal B type locally ad-vanced breast cancer

WANG Mei; WANG Haixin; HU Wei; XIONG Anwen; WU Meihong; LI Yongmei; WANG Wei; WANG Yajie

Abstract：Objective To screen prognostic genes for neoadjuvant chemotherapy in patients with locally advanced breast cancer of luminal B type. Methods Ten locally advanced breast cancer patients of luminal B type were underwent DA regimen as neoadjuvant chemotherapy( docetaxel 75mg/m2 iv, d1;epirubicin 80 mg/m2 iv, d1 , 3 weeks as a cycle for 4 cycles) . Based on RECIST1?1 standard, 10 patients were divided into pathological complete remission( pCR) group( n=3) and non-pathological complete remission( npCR) group ( n=7) . GeneChip human genome was used to screen prognostic genes for neoadjuvant chemotherapy in 10 luminal B breast cancer pa-tients. Florescence quantitative PCR was conducted to confirm the different gene expression. Results Compared with npCR patients, 231 genes expression were up-regulated, 195 genes expression were down-regulated in tumor samples of pCR patients;Compared with peri-tumor tissues, 357 genes expression were up-regulated and 544 genes expression were down-regulated in tumor samples of pCR patients. Compared with peri-tumor tissues, 143 genes expression were up-regulated and 101 genes expression were down-regulated in the tumor samples of npCR patients. Compared with npCR patients, 98 genes expression were up-regulated and 67 genes expression were down-regu-lated in peri-tumor samples of pCR patients. Statistically significant differences in gene expressions were noted in pCR group vs. npCR group, including 3 up-regulated genes of CYP4Z1, FGFL6 and BCAR4, as well as 3 down-regulated genes of FABP4, S100B and AL-PH1L1. The expression of CYP4Z1 and BCAR4 in pCR patients was significantly lower than that of npCR patients(P<0?05) confirmed by florescence quantitative PCR. Conclusion In patients with luminal B locally advanced breast cancer, lower expression of CYP4Z1 and BCAR4 may be associated with higher pCR rates in neoadjuvant chemotherapy receiving DA regimen.